Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.53 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.53 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7370215 | 0.83 | F2 (0.56) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL446590 | 0.73 | F2 (0.44) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL14165295 | 0.73 | F2 (0.52) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL6592968 | 0.70 | F2 (0.32) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL9965535 | 0.69 | F2 (0.50) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL16298358 | 0.68 | F2 (0.40) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL2369612 | 0.68 | F2 (0.40) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL2369616 | 0.68 | F2 (0.40) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL14493144 | 0.67 | F2 (0.39) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL2339827 | 0.67 | F2 (0.50) | F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234033-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS | 2005-10-20 | — | — | US | disclosed |
| EP-1261608-B1 | DIKETOPIPERAZINE DERIVATIVES TO INHIBIT THROMBIN | BEST EXPRESS WORLDWIDE LTD TRU (VG) | 2004-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234033-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC11, HDAC10 | F2 4793/4885PRSS1 1241/4885PRSS2 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.